Tags & Categorías

Eli Lilly Hints That It May Pursue "Branded Biosimilars" of Its Own Products

The comment period has recently closed for the FDA’s proposed approach to the transition of insulins and other products that have historically been...

Kern impulsa la formación en biosimilares de los residentes en reumatología

Kern Pharma Biologics contribuye a la formación de los residentes de reumatología de tercer y cuarto año patrocinando las “Becas para Estancias C...

EMA approval for adalimumab biosimilars Idacio and Kromeya

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 31 January 2019 that it had recommended gra...

Mundipharma Launches Biosimilar Pegfilgrastim in Germany, the Netherlands, and Ireland

Mundipharma announced today that it has launched Pelmeg, a biosimilar pegfilgrastim referencing Neulasta, in Germany, the Netherlands, and Ireland.

Pfizer's Trastuzumab Biosimilar Is Equivalent to EU Reference in MBC

Results from the phase 3 REFLECTIONS B327-02 study in patients with HER2-positive metastatic breast cancer (MBC) were first presented in abstract fo...

NHS Provides Update on Biosimilar Adalimumab With a Focus on ISRs

Biosimilar adalimumab is making its way to patients, some of whom have expressed concerns about the presence of citrate in some of the available biosi...

More Research Finds Low Awareness of Biosimilars Among Oncology Providers

While a majority of survey respondents said that they were at least somewhat familiar with current developments in oncology biosimilars, analyses of o...

Coherus Settles With AbbVie, Sues Amgen, Over Biosimilar Adalimumab

Coherus BioSciences announced on Friday that it has become the latest biosimilar developer to settle with AbbVie, maker of the brand-name adalimumab, ...

Creating and Sustaining Best Practices in Launching Biosimilars

Before launching into a discussion of what firms need to consider when identifying “best practices” to get a biosimilar up and running in a new ma...

Alvotech Raises $300 Million to Develop Biosimilars

Drug maker Alvotech announced this week that it has raised $300 million, through a private bond offering, that it will used to continue its growth, re...